S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.11 (-0.25%)
MSFT   290.73 (-0.20%)
META   175.26 (+0.23%)
GOOGL   120.46 (+0.76%)
AMZN   141.95 (-0.11%)
TSLA   908.51 (-0.38%)
NVDA   187.11 (+2.05%)
NIO   19.84 (-1.20%)
BABA   90.71 (+1.05%)
AMD   100.43 (+2.20%)
MU   62.95 (+2.16%)
T   18.49 (+0.38%)
CGC   3.71 (-8.62%)
F   16.12 (+0.56%)
GE   79.24 (-0.85%)
DIS   122.61 (-0.16%)
AMC   19.60 (-8.24%)
PYPL   99.83 (+0.41%)
PFE   48.66 (-1.24%)
NFLX   244.84 (+1.53%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.11 (-0.25%)
MSFT   290.73 (-0.20%)
META   175.26 (+0.23%)
GOOGL   120.46 (+0.76%)
AMZN   141.95 (-0.11%)
TSLA   908.51 (-0.38%)
NVDA   187.11 (+2.05%)
NIO   19.84 (-1.20%)
BABA   90.71 (+1.05%)
AMD   100.43 (+2.20%)
MU   62.95 (+2.16%)
T   18.49 (+0.38%)
CGC   3.71 (-8.62%)
F   16.12 (+0.56%)
GE   79.24 (-0.85%)
DIS   122.61 (-0.16%)
AMC   19.60 (-8.24%)
PYPL   99.83 (+0.41%)
PFE   48.66 (-1.24%)
NFLX   244.84 (+1.53%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.11 (-0.25%)
MSFT   290.73 (-0.20%)
META   175.26 (+0.23%)
GOOGL   120.46 (+0.76%)
AMZN   141.95 (-0.11%)
TSLA   908.51 (-0.38%)
NVDA   187.11 (+2.05%)
NIO   19.84 (-1.20%)
BABA   90.71 (+1.05%)
AMD   100.43 (+2.20%)
MU   62.95 (+2.16%)
T   18.49 (+0.38%)
CGC   3.71 (-8.62%)
F   16.12 (+0.56%)
GE   79.24 (-0.85%)
DIS   122.61 (-0.16%)
AMC   19.60 (-8.24%)
PYPL   99.83 (+0.41%)
PFE   48.66 (-1.24%)
NFLX   244.84 (+1.53%)
S&P 500   4,284.37 (+0.24%)
DOW   33,969.58 (-0.03%)
QQQ   329.21 (+0.22%)
AAPL   174.11 (-0.25%)
MSFT   290.73 (-0.20%)
META   175.26 (+0.23%)
GOOGL   120.46 (+0.76%)
AMZN   141.95 (-0.11%)
TSLA   908.51 (-0.38%)
NVDA   187.11 (+2.05%)
NIO   19.84 (-1.20%)
BABA   90.71 (+1.05%)
AMD   100.43 (+2.20%)
MU   62.95 (+2.16%)
T   18.49 (+0.38%)
CGC   3.71 (-8.62%)
F   16.12 (+0.56%)
GE   79.24 (-0.85%)
DIS   122.61 (-0.16%)
AMC   19.60 (-8.24%)
PYPL   99.83 (+0.41%)
PFE   48.66 (-1.24%)
NFLX   244.84 (+1.53%)
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$373.34
-0.67 (-0.18%)
(As of 08/18/2022 02:41 PM ET)
Add
Compare
Today's Range
$366.68
$375.90
50-Day Range
$327.37
$407.78
52-Week Range
$318.50
$695.18
Volume
21,210 shs
Average Volume
588,182 shs
Market Capitalization
$31.08 billion
P/E Ratio
48.17
Dividend Yield
N/A
Price Target
$483.57

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
29.6% Upside
$483.57 Price Target
Short Interest
Healthy
2.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.36mentions of IDEXX Laboratories in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.49%
From $7.91 to $9.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.12 out of 5 stars

Medical Sector

13th out of 1,122 stocks

Diagnostic Substances Industry

1st out of 17 stocks

IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Stock Down 2.2 %

Shares of NASDAQ:IDXX opened at $374.01 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 1.68. The company has a fifty day simple moving average of $370.83 and a 200 day simple moving average of $437.92. The firm has a market cap of $31.14 billion, a PE ratio of 48.26, a price-to-earnings-growth ratio of 5.09 and a beta of 1.14. IDEXX Laboratories has a 12-month low of $318.50 and a 12-month high of $695.18.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $500.00 to $420.00 in a research note on Monday, August 8th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $603.00 to $573.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Bank of America cut shares of IDEXX Laboratories from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. The Goldman Sachs Group raised shares of IDEXX Laboratories from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $530.00 to $435.00 in a research report on Thursday, July 21st. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $700.00 to $582.00 and set an "overweight" rating on the stock in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $483.57.

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

IDEXX Laboratories Stock Is Very Expensive
IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $420.00
Stifel Nicolaus Lowers IDEXX Laboratories (NASDAQ:IDXX) to Hold
IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $490.00
IDEXX Laboratories Slashes FY22 Outlook - Update
IDEXX Laboratories (NASDAQ:IDXX) PT Lowered to $420.00
IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Down to $393.51
StockNews.com Lowers IDEXX Laboratories (NASDAQ:IDXX) to Hold
Nasdaq 100 Movers: IDXX, ISRG
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
11/02/2021
Today
8/18/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$483.57
High Stock Price Forecast
$582.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+29.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
24.89%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$9.78 per share
Book Value
$5.49 per share

Miscellaneous

Free Float
81,539,000
Market Cap
$31.08 billion
Optionable
Optionable
Beta
1.14

Social Links















IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2022?

8 brokerages have issued 1 year price targets for IDEXX Laboratories' stock. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's share price to reach $483.57 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2022?

IDEXX Laboratories' stock was trading at $658.46 at the beginning of the year. Since then, IDXX stock has decreased by 43.2% and is now trading at $374.01.
View the best growth stocks for 2022 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported $2.03 EPS for the quarter, beating analysts' consensus estimates of $1.88 by $0.15. The company earned $810.42 million during the quarter, compared to analyst estimates of $793.26 million. IDEXX Laboratories had a net margin of 20.07% and a trailing twelve-month return on equity of 104.47%. During the same quarter in the previous year, the company earned $1.69 EPS.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $7.77-$8.05 for the period, compared to the consensus earnings per share estimate of $8.27. The company issued revenue guidance of $3.31 billion-$3.38 billion, compared to the consensus revenue estimate of $3.42 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), FMR LLC (2.48%), Franklin Resources Inc. (1.46%), Brown Advisory Inc. (1.34%), Northern Trust Corp (1.08%) and Price T Rowe Associates Inc. MD (1.02%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $374.01.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $31.14 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.75 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.